黄葵胶囊通过Keap1/Nrf2/HO-1通路调控色氨酸代谢改善糖尿病肾病
该研究在db/db小鼠和高糖HK-2细胞模型中观察黄葵胶囊对糖尿病肾病的作用及机制。结果显示黄葵胶囊可抑制血糖和UACR升高、改善肾损伤,并通过Keap1/Nrf2/HO-1通路降低ROS、调控色氨酸代谢和5-HT通路。
要点
- 黄葵胶囊可抑制db/db小鼠血糖和UACR升高并改善肾损伤。
- 其机制涉及调控色氨酸代谢及Keap1/Nrf2/HO-1通路降低ROS。
- 抑制5-HT2AR可减少5-HT合成并改善高糖诱导的肾损伤。
核心结论
- 黄葵胶囊通过调控色氨酸代谢和Keap1/Nrf2/HO-1通路抑制db/db小鼠及HK-2细胞的肾损伤和氧化应激损伤。
研究设计与样本
- db/db小鼠随机分为DN、HKC-L、HKC-H和IRB组,db/m小鼠为Control组,并行HE、Masson和PAS染色验证抗DN作用。
- 体外采用高糖损伤HK-2细胞模型,并以5-HT2AR抑制剂盐酸沙格雷酯联合黄葵胶囊验证5-HT通路作用。
主要发现
- 黄葵胶囊显著抑制血糖和尿白蛋白/肌酐比值(UACR)升高,改善小鼠肾脏损伤体征。
- 黄葵胶囊通过Keap1/Nrf2/HO-1通路降低ROS水平并改善氧化应激损伤。
- 代谢组学分析显示色氨酸代谢参与黄葵胶囊改善DN的过程,黄葵胶囊可调控5-HT通路。
- 黄葵胶囊通过Nrf2通路改善高糖HK-2细胞模型的肾脏和氧化应激损伤。
- 抑制5-HT2AR可显著抑制5-HT合成并改善高糖诱导的肾损伤。
临床怎么用
- 为黄葵胶囊临床用于糖尿病肾病治疗提供了调控色氨酸代谢和Keap1/Nrf2/HO-1通路的机制依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetic nephropathy (DN) is a serious complication of diabetes and one of the leading causes of end-stage renal disease. Huangkui capsule (HKC), a traditional Chinese patent medicine, is widely used in clinical practice for the treatment of chronic glomerulonephritis. However, the therapeutic effects and underlying mechanisms of HKC in DN remain poorly understood. METHODS: DN was induced in db/db mice, which were randomly divided into the DN, HKC-L, HKC-H and IRB groups, and db/m mice served as the Control group. Biochemical indices of blood and urine samples from the mice were measured, and HE staining, Masson staining and PAS staining were used to verify the anti-DN effect of HKC. The levels of ROS and the expression of Nrf2 pathway-related proteins and mRNAs were detected. Metabonomic analysis was used to investigate the role of tryptophan metabolism in the regulation of DN by HKC. HK-2 cells were used to establish a model of high-glucose (HG) injury in vitro, and HKC treatment was given for supplementary verification. Sarpogrelate hydrochloride (SH) combined with HKC, a 5-HT2AR inhibitor, was used to verify the effect of the 5-HT pathway in an in vitro model. RESULTS: Treatment with HKC significantly inhibited the increase in blood glucose and Urinary albumin/creatinine ratio (UACR), improved kidney injury signs in mice, reduced the level of ROS and improved oxidative stress injury through the Keap1/ Nrf2/HO-1 pathway. Metabonomic analysis revealed that tryptophan metabolism is involved in the process by which HKC improves DN, and HKC can regulate the 5-HT pathway to improve the renal injury by oxidative stress regulation. HKC treatment also significantly improved the renal and oxidative stress injuries in HG HK-2 cell model through the Nrf2 pathway in vitro. SH administration revealed that inhibiting 5-HT2AR could significantly inhibit the synthesis of 5-HT and improve the renal injury induced by HG. CONCLUSION: Our study demonstrate that HKC can inhibit kidney injury and oxidative stress injury in db/db mice and HK-2 cells by regulating tryptophan metabolism and the Keap1/Nrf2/HO-1 pathway, which provides new insight for the clinical use of HKC for treatment of DN.
引用
- Su J, Zhang Y, Wang X, et al. Huangkui capsules regulate tryptophan metabolism to improve diabetic nephropathy through the Keap1/Nrf2/HO-1 pathway. Front Pharmacol. 2025. PMID: 40371325. doi:10.3389/fphar.2025.1535352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。